Abstract: Provided herein is a novel Akkermansia muciniphila strain. Compositions comprising the strain are also provided. Methods comprising administering the compositions to a subject in need thereof are also provided. In some embodiments, provided are methods of treating a metabolic disorder in a subject, such methods comprising administering to the subject a composition of the present disclosure in an amount effective to treat the metabolic disorder in the subject. Methods comprising culturing the novel strain are also provided.

Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: Provided are methods of increasing ursodeoxycholic acid (UDCA) levels in a mammalian subject. The methods comprise orally administering to the mammalian subject a composition comprising one or more bacterial strains in an amount effective to increase UDCA levels in the mammalian subject. Also provided are methods of antagonizing farnesoid X receptor (FXR) in intestinal cells of a mammalian subject. Such methods comprise orally administering to the mammalian subject a composition comprising one or more bacterial strains in an amount effective to antagonize FXR in intestinal cells of the mammalian subject. In certain embodiments, the mammalian subject has diabetes, e.g., type 2 diabetes. According to some embodiments, the mammalian subject suffers from a liver disorder, obesity, or both. In certain embodiments, the mammalian subject has colorectal cancer. According to some embodiments, the mammalian subject has gallstones.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.

Abstract: The disclosure provides microbial compositions (e.g., compositions comprising one or more microbes or protein components thereof), that can be administered to subjects to confer beneficial effects. Disclosed compositions can, for example, be useful in reducing visceral hypersensitivity, or pain in response to colorectal distension.

Abstract: Methods to increase viability and revivability of bacteria compared to their wild type counterparts, are disclosed herein. New strains of an anerobic bacteria is also disclosed obtained by the methods described herein. Further, disclosed are compositions comprising these bacteria as well as methods of treatment including the use of the bacteria described.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: Administering a composition comprising at least one mucin-regulating and at least one butyrate-producing microbe can provide a therapeutic effect for subjects having prediabetes or type 2 diabetes. Therapeutic effects can include a reduction in hemoglobin A1C levels, a reduction in glucose area under the curve after a meal tolerance test, or a reduction in the fasting glucose level.

Abstract: The disclosure provides compositions and methods for therapeutic administration of the compositions to treat comorbidities associated with gut dysbiosis. The disclosure also provides compositions and methods for increasing engraftment of administered microbes. The disclosure also provides methods for stool sample collection.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.

Abstract: The present disclosure provides methods for profiling a microbiome and therapeutic compositions for treatment. Additionally, the methods, systems, compositions and kits provided herein are directed to assessing or predicting health status in a subject. Some of the embodiments include generating a report.

Abstract: Disclosed herein are methods and compositions for treatment of a microbiome associated disorder. Further, disclosed herein are methods and compositions for modulating short chain fatty acid production in a subject.